EMR Emerson Electric (EMR) Insider Trading, Ownership & Congress Trades
Semiconductors & Electronics · Electronic & other electrical equipment (no computer equip) · CIK 0000032604
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
1,095
13F, latest reported quarter
What the filings say about EMR
Insiders, 180 days
-$4.4M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: sale, 2026-09-17
Planned sales (Form 144), 90 days
$2.7M
2 notices
Emerson Electric insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, EMERSON ELECTRIC CO insiders sold a net $4.4M of stock across 34 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Mar 10, 2026.
- The trade is 3.6% of the 271,743 shares held after it.
- 1 other insider sold within 30 days.
- 1,095 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Karsanbhai Surendralal Lanca sold about $1.6M of EMR on Aug 11, 2026; 1 other insider sold within 30 days and 1,095 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 12, 2025.
- The trade is 3.1% of the 238,516 shares held after it.
- 1 other insider sold within 30 days.
- 1,095 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Sustain Officer Train Michael H. sold about $1.2M of EMR on Aug 6, 2026; 1 other insider sold within 30 days and 1,095 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 15, 2023.
- The trade is 7.2% of the 159,639 shares held after it.
- No other insider sold within 30 days.
- 1,095 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice Pres & COO Krishnan Ram R. sold about $1.6M of EMR on Jun 1, 2026, the largest insider sale at the company since 2025; 1,095 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Dec 3, 2025.
- The trade is 2.0% of the 281,393 shares held after it.
- 2 other insiders sold within 30 days.
- 1,095 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Karsanbhai Surendralal Lanca sold about $811.2K of EMR on Mar 10, 2026; 2 other insiders sold within 30 days and 1,095 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 12, 2025.
- The trade is 6.1% of the 24,349 shares held after it.
- 3 other insiders sold within 30 days.
- 1,095 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LEVATICH MATTHEW S sold about $239.3K of EMR on Feb 10, 2026; 3 other insiders sold within 30 days and 1,095 funds added in the latest 13F quarter.34 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.4M over 180 days
-$2.7M over 90 days
more than 52% of Semiconductors & Electronics
Congress
1 member bought in the last year
the lowest in Semiconductors & Electronics
Funds
1,095 funds bought in last quarter
more than 92% of Semiconductors & Electronics
Revenue
+3.0% year over year
below 63% of Semiconductors & Electronics
Margin
12.7% net margin
more than 79% of Semiconductors & Electronics
Buybacks
$898.0M repurchased, FY to 2026-06-30
more than 89% of Semiconductors & Electronics
Short interest
1.6% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
below 74% of Semiconductors & Electronics
What changed in the last 30 days
Oct 13Rep. Kevin Hern sold $15K to $50K, disclosed 26 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch EMR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+23.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EMR: institutional holders (13F)
13F holdings, latest reported quarter
43,265,282 sh
$6.2B
36,588,248 sh
$5.2B
27,678,497 sh
$4.0B
18,366,373 sh
$2.6B
13,312,414 sh
$1.9B
Congress trades in EMR
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-17 · disclosed 26 days later
$15,001 - $50,000
Sold 2026-09-14 · disclosed 11 days later
$1,001 - $15,000
Sold 2026-09-14 · disclosed 11 days later
$15,001 - $50,000
Sold 2026-07-30 · disclosed 15 days later
$1,001 - $15,000
Bought 2025-11-05 · disclosed 34 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EMR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Karsanbhai Surendralal Lanca
Filed 2026-08-11
$1.6M
Michael H. Train
Filed 2026-08-06
$1.2M
EMR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Robotics ETF
$4.7M position · as of 2026-06-30
4.9%
Invesco Comstock Select Fund
$32.2M position · as of 2026-07-31
3.8%
Core Alternative ETF
$993.3K position · as of 2026-07-31
3.6%
Genter Dividend Income Fund
$1.6M position · as of 2026-07-31
3.1%
DAVENPORT INSIDER BUYING FUND
$2.9M position · as of 2026-06-30
3.0%
MONONGAHELA ALL CAP VALUE FUND
$1.3M position · as of 2026-07-31
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.4M sold by insiders over 180 days, 1,095 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $2.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EMR financials
Revenue growth
+3.0%
XBRL, annual
Net margin
12.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EMR
| FY Sep 2025 | $18.0B |
| FY Sep 2024 | $17.5B |
| FY Sep 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2022 | $19.6B |
| Jun 2026 | $4.9B |
| Mar 2026 | $4.6B |
| Dec 2025 | $4.3B |
| Sep 2025 | $4.9B |
| Jun 2025 | $4.6B |
| Mar 2025 | $4.4B |
| Dec 2024 | $4.2B |
| Sep 2024 | $4.6B |
At each fiscal year end
Single quarter
Net margin, TTM
+13.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EMR
| FY Sep 2025 | +12.7% |
| FY Sep 2024 | +11.3% |
| FY Sep 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2022 | +16.5% |
| Jun 2026 | +14.7% |
| Mar 2026 | +13.5% |
| Dec 2025 | +13.9% |
| Sep 2025 | +13.1% |
| Jun 2025 | +12.9% |
| Mar 2025 | +10.9% |
| Dec 2024 | +14.0% |
| Sep 2024 | +21.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.5B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EMR
| FY Sep 2025 | $2.7B |
| FY Sep 2024 | $2.9B |
| FY Sep 2023 | $274.0M |
| FY Dec 2022 | $2.5B |
| FY Sep 2022 | $2.6B |
| Jun 2026 | $1.3B |
| Mar 2026 | $694.0M |
| Dec 2025 | $602.0M |
| Sep 2025 | $842.0M |
| Jun 2025 | $977.0M |
| Mar 2025 | $154.0M |
| Dec 2024 | $694.0M |
| Sep 2024 | $916.0M |
At each fiscal year end
Single quarter
Debt to equity
0.64x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity EMR
| FY Sep 2025 | 0.65x |
| FY Sep 2024 | 0.36x |
| FY Sep 2023 | 0.39x |
| FY Dec 2022 | 0.93x |
| FY Sep 2022 | 1.00x |
| Jun 2026 | 0.64x |
| Mar 2026 | 0.66x |
| Dec 2025 | 0.66x |
| Sep 2025 | 0.65x |
| Jun 2025 | 0.72x |
| Mar 2025 | 0.75x |
| Dec 2024 | 0.37x |
| Sep 2024 | 0.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.30x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt EMR
| FY Sep 2025 | 0.24x |
| FY Sep 2024 | 0.43x |
| FY Sep 2023 | 0.08x |
| FY Dec 2022 | 0.28x |
| FY Sep 2022 | 0.28x |
| Jun 2026 | 0.30x |
| Mar 2026 | 0.27x |
| Dec 2025 | 0.23x |
| Sep 2025 | 0.24x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.48x |
| Sep 2024 | 0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+12.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity EMR
| FY Sep 2025 | +10.9% |
| FY Sep 2024 | +9.3% |
| FY Sep 2023 | +85.1% |
| FY Dec 2022 | +44.5% |
| FY Sep 2022 | +31.9% |
| Jun 2026 | +12.8% |
| Mar 2026 | +12.4% |
| Dec 2025 | +11.3% |
| Sep 2025 | +10.9% |
| Jun 2025 | +13.0% |
| Mar 2025 | +11.9% |
| Dec 2024 | +11.7% |
| Sep 2024 | +9.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EMR
| FY Sep 2025 | +5.3% |
| FY Sep 2024 | +4.5% |
| FY Sep 2023 | +33.7% |
| FY Dec 2022 | +14.8% |
| FY Sep 2022 | +10.7% |
| Jun 2026 | +6.1% |
| Mar 2026 | +5.8% |
| Dec 2025 | +5.5% |
| Sep 2025 | +5.3% |
| Jun 2025 | +6.0% |
| Mar 2025 | +5.4% |
| Dec 2024 | +5.4% |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital EMR
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed EMR
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Sep 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing EMR
| FY Sep 2025 | 32.47x |
| FY Sep 2024 | 31.98x |
| FY Sep 2023 | 4.21x |
| FY Dec 2022 | 12.19x |
| FY Sep 2022 | 13.53x |
| Jun 2026 | n/a |
| Mar 2026 | 32.03x |
| Dec 2025 | 32.45x |
| Sep 2025 | 32.47x |
| Jun 2025 | 28.67x |
| Mar 2025 | 26.23x |
| Dec 2024 | 29.58x |
| Sep 2024 | 31.98x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$98.6B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2021-12-31
Enterprise value EMR
| FY Sep 2025 | $82.2B |
| FY Sep 2024 | $65.6B |
| FY Sep 2023 | $58.6B |
| FY Dec 2022 | $60.1B |
| FY Sep 2022 | $48.9B |
| Jun 2026 | $88.2B |
| Mar 2026 | $82.0B |
| Dec 2025 | $83.3B |
| Sep 2025 | $82.2B |
| Jun 2025 | $84.5B |
| Mar 2025 | $71.3B |
| Dec 2024 | $72.8B |
| Sep 2024 | $65.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield EMR
| FY Sep 2025 | +3.6% |
| FY Sep 2024 | +4.7% |
| FY Sep 2023 | +0.5% |
| FY Dec 2022 | +4.6% |
| FY Sep 2022 | +6.1% |
| Jun 2026 | +4.3% |
| Mar 2026 | +4.2% |
| Dec 2025 | +3.5% |
| Sep 2025 | +3.6% |
| Jun 2025 | +3.7% |
| Mar 2025 | +4.5% |
| Dec 2024 | +4.7% |
| Sep 2024 | +4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing EMR
| FY Sep 2025 | 1.79x |
| FY Sep 2024 | n/a |
| FY Sep 2023 | 0.01x |
| FY Dec 2022 | 0.17x |
| FY Sep 2022 | 0.33x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 1.79x |
| Jun 2025 | 0.51x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $18.0B | $17.5B | $15.2B | $1.7B |
| Gross profit | $9.5B | $8.9B | $7.4B | n/a |
| Net income | $2.3B | $2.0B | $13.2B | n/a |
| EPS (diluted) | 4.04 | 3.43 | 22.88 | n/a |
| Operating cash flow | $3.1B | $3.3B | $637.0M | n/a |
| Long-term debt | $8.3B | $7.2B | $7.6B | $8.2B |
| Buybacks | $1.2B | $435.0M | $2.0B | n/a |
| Dividends paid | $1.2B | $1.2B | $1.2B | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
EMR Stock Sonar score 6/7 axes
Find similar shapesCompareEMR ranks highest on risk and compliance (70th percentile) and profitability (69th), and lowest on insider conviction (25th), among Semiconductors & Electronics peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EMR filings, in plain words
Are Emerson Electric insiders buying or selling EMR?
In the 180 days to 2026-10-28, Emerson Electric insiders were net sellers, a net $4.4M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded EMR?
Yes. In the year to 2026-10-28, 1 House member disclosed buying EMR and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-17.
Are there planned insider sales of EMR?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.7M of stock; the latest, by Karsanbhai Surendralal Lanca, was filed 2026-08-11.
Read the full summary
In the 180 days to 2026-10-28, Emerson Electric insiders were net sellers of EMR, a net $4.4M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying EMR and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-17. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
